Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

aTyr Pharma Inc ATYR

aTyr Pharma, Inc. is a clinical-stage biotechnology company. The Company is leveraging intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase derived therapy that selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve aberrant inflammation without immune suppression and prevent the progression of fibrosis. ATYR0101 is a fusion protein derived from a domain of aspartyl-tRNA synthetase (DARS). ATYR0101 binds directly to latent-transforming growth factor beta-binding protein 1 (LTBP1), which regulates transforming growth factor beta (TGFb). Its ATYR0750 is a fusion protein derived from a domain of alanyl-tRNA synthetase (AARS).


NDAQ:ATYR - Post by User

Bullboard Posts
Post by fedoraon May 09, 2001 9:33am
408 Views
Post# 3716059

Where are you Posters?...

Where are you Posters?...I have been patiently waiting to see some other investors post something of value on this board...obviously to no avail. So I guess that I will have to do it myself. This stock looks to be going forward quite nicely. If you check the stockscores.com page and put in life yu will see that the momentum is going in the right direction. Furthermore, the Florida acquisition should bolster the revenues and bottom line. As they diversify to handle other industry segments, they should also be improving revenues and trhe bottom line. They handle their expenses very responsibly in addition. I believe that a $20-$23 price by years end is quite forseeable as expansion seems to be in the cards. Go Longs Go!!! Cheers to LIFE!!!!!
Bullboard Posts